Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction.
Mohammad Reza AfshaniEkhlas TorfiNehzat AkiashAlireza JahanshahiAsghar MohamadiOmid SherafatPublished in: Acta cardiologica (2024)
Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.
Keyphrases
- heart failure
- left ventricular
- type diabetes
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- aortic stenosis
- acute myocardial infarction
- cardiac resynchronization therapy
- glycemic control
- atrial fibrillation
- hypertrophic cardiomyopathy
- patient reported outcomes
- combination therapy
- adipose tissue
- patient reported
- percutaneous coronary intervention